Knight Therapeutics (GUD) Competitors C$6.50 +0.10 (+1.56%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesBuy This Stock GUD vs. THCX, TLRY, CRON, ACB, WEED, FIRE, OGI, CPH, EPI, and ICCShould you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Hydropothecary (THCX), Tilray Brands (TLRY), Cronos Group (CRON), Aurora Cannabis (ACB), Canopy Growth (WEED), Supreme Cannabis (FIRE), Organigram (OGI), Cipher Pharmaceuticals (CPH), ESSA Pharma (EPI), and ICC Labs (ICC). These companies are all part of the "drug manufacturers - specialty & generic" industry. Knight Therapeutics vs. Its Competitors Hydropothecary Tilray Brands Cronos Group Aurora Cannabis Canopy Growth Supreme Cannabis Organigram Cipher Pharmaceuticals ESSA Pharma ICC Labs Knight Therapeutics (TSE:GUD) and Hydropothecary (CVE:THCX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability. Does the media prefer GUD or THCX? In the previous week, Knight Therapeutics had 1 more articles in the media than Hydropothecary. MarketBeat recorded 1 mentions for Knight Therapeutics and 0 mentions for Hydropothecary. Knight Therapeutics' average media sentiment score of 0.20 beat Hydropothecary's score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Knight Therapeutics Neutral Hydropothecary Neutral Do analysts rate GUD or THCX? Knight Therapeutics presently has a consensus target price of C$7.15, suggesting a potential upside of 10.00%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Knight Therapeutics is more favorable than Hydropothecary.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Knight Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Hydropothecary 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings & valuation, GUD or THCX? Hydropothecary has lower revenue, but higher earnings than Knight Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKnight TherapeuticsC$348.70M1.89-C$30.73M-C$0.30-21.70HydropothecaryN/AN/AN/AN/AN/A Do institutionals and insiders believe in GUD or THCX? 12.6% of Knight Therapeutics shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is GUD or THCX more profitable? Hydropothecary has a net margin of 0.00% compared to Knight Therapeutics' net margin of -8.81%. Hydropothecary's return on equity of 0.00% beat Knight Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Knight Therapeutics-8.81% -4.04% 0.51% Hydropothecary N/A N/A N/A SummaryKnight Therapeutics beats Hydropothecary on 10 of the 12 factors compared between the two stocks. Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GUD vs. The Competition Export to ExcelMetricKnight TherapeuticsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$657.48MC$1.70BC$5.69BC$9.24BDividend YieldN/A2.89%3.99%6.55%P/E Ratio-21.70105.5879.6623.37Price / Sales1.891,223.92536.5218.46Price / Cash3.8510.3737.7083.29Price / Book0.8511.3910.575.35Net Income-C$30.73MC$20.70BC$3.27BC$301.20M7 Day Performance0.78%0.91%0.61%2.94%1 Month Performance5.86%5.15%5.43%5.18%1 Year Performance18.18%5.19%50.37%32.88% Knight Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GUDKnight Therapeutics0.6758 of 5 starsC$6.50+1.6%C$7.15+10.0%+15.7%C$657.48MC$348.70M-21.70725THCXHydropothecaryN/AC$5.30+6.6%N/A+0.0%C$949.11MN/A0.00N/AHigh Trading VolumeTLRYTilray BrandsN/AC$1.45-7.6%N/A-11.8%C$934.33MC$610.34M-3.502,650Gap DownCRONCronos GroupN/AC$3.44-2.0%N/A+23.1%C$908.38MC$76.86M-19.14450News CoverageACBAurora Cannabis0.1443 of 5 starsC$6.58-6.9%C$8.75+33.0%-3.1%C$359.98MC$195.83M-8.131,073WEEDCanopy Growth0.325 of 5 starsC$1.73-8.9%C$1.55-10.4%-63.8%C$278.30MC$519.68M-0.252,700Positive NewsGap DownFIRESupreme CannabisN/AN/AN/AN/AC$259.40MC$53.29M-10.97400OGIOrganigram2.4937 of 5 starsC$2.09-1.4%C$3.33+59.1%-4.0%C$258.20MC$180.58M-4.42987CPHCipher Pharmaceuticals0.3236 of 5 starsC$14.26-1.6%C$14.75+3.4%-11.7%C$256.01MC$19.03M15.755EPIESSA PharmaN/AC$8.20+7.2%N/A+0.0%C$237.87MN/A-8.2725ICCICC LabsN/AC$1.62-5.8%N/A+0.0%C$223.64MC$533.68K95.29N/AGap Up Related Companies and Tools Related Companies THCX Alternatives TLRY Alternatives CRON Alternatives ACB Alternatives WEED Alternatives FIRE Alternatives OGI Alternatives CPH Alternatives EPI Alternatives ICC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:GUD) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access